Before a MedTech company adds headcount, channels, or spend, founders and CEOs should pressure-test the go-to-market plan. Here are the questions we use to find the weak points first.
Scaling a go-to-market plan multiplies whatever is already in it, including the parts that haven't been tested yet.
There's a moment in most MedTech companies when the conversation turns to scale. Clearance is in hand, a few early accounts are live, and the board wants to know when the commercial engine gets bigger. More reps, more territories, a bigger conference presence, a new campaign.
That's a reasonable instinct. Growth is the point.
What we see in our work with MedTech companies is that the plan being scaled often still carries assumptions from much earlier in the company's life. The buyer was defined before anyone sat across from a value analysis committee. The message was written around the device before the team learned what hospitals actually care about. The sales process works because one or two people know how to make it work.
When those assumptions get scaled, the cracks get bigger too. That's why the strongest founders and CEOs we work with pressure-test the GTM before they put more weight on it.
Why Scale Makes Small Problems Expensive
A go-to-market plan that's slightly off can still produce early wins. A founder who knows the clinical story cold can close deals the rest of the team can't. A champion surgeon can carry an account through a process that would stall anywhere else.
Those wins are real, and they're also hard to repeat.
Once you add reps, territories, or channels, every gap in the plan gets copied. An unclear buyer becomes ten reps chasing the wrong stakeholder. A message built around features becomes a campaign that gets clicks and no meetings. A sales motion that lives in one person's head becomes a ramp time nobody can explain.
A pressure-test is how you find those gaps while they're still cheap to fix.
Start With the Buyer, Then the Whole Buying Group
The first question is simple to ask and harder to answer well: who actually decides to buy, and what do they need to believe before they say yes?
In MedTech, that's rarely one person. The clinician who loves the technology, the administrator watching the budget, the value analysis committee, and the procurement team each have a different reason to say no. A strong GTM plan names each of them and knows what moves them.
Questions worth asking your team:
Can everyone on the commercial team name the economic buyer, the clinical champion, and the gatekeepers for a typical account?
Do we know what evidence each of them needs to see?
Where have deals stalled so far, and which stakeholder was in the room when they did?
If the answers differ depending on who you ask, that's the first thing to fix.
Test Whether the Story Holds Without the Founder
Founders and CEOs are usually the best storytellers in the company. They know why the technology matters, and they can adapt the story to any room.
The pressure-test is whether the story still works when someone else tells it.
Ask three people on your team to explain what the company does and why a hospital should care, in two sentences. Then compare. If you hear three different stories, the market is hearing three different stories too. If all three lead with the device and none lead with the clinical or economic outcome, the message hasn't finished translating from clinical value to commercial value.
A commercial narrative that holds up across the team is one of the clearest signs a company is ready to scale it.
Check the Beachhead Before You Expand It
Most MedTech companies start in a focused segment: a specialty, a site of care, a region, or a type of account. That focus is a strength. It's where the company builds evidence, references, and a repeatable win.
Before expanding, it's worth asking whether the beachhead has actually been won.
Do we have referenceable accounts that would take a call from a peer?
Can we explain why we win in this segment in a way that's specific enough to repeat?
Is the next segment a natural extension, or a new market with a new buyer and a new story?
Expansion goes faster when the first market has already given you proof the next one will recognize.
Pressure-Test the Sales Motion
A repeatable sales motion has defined stages, clear criteria for moving between them, and a shared understanding of what happens at each step. Without that, every new rep builds their own version of the process, and forecasting turns into guesswork.
Look at your last several closed deals and your last several stalled ones. Map where each one moved and where it slowed down. The pattern usually points to a specific stage, often the point where clinical enthusiasm has to turn into budget approval.
That stage is where the plan needs work before more people are added to it.
Make Sure the Numbers Tell the Same Story
Founders and CEOs carry two versions of the commercial plan: the one in the board deck and the one the team runs every day. A pressure-test asks whether they match.
If the plan assumes a sales cycle, an adoption curve, or a number of accounts per rep, check those assumptions against what has actually happened so far. Where they differ, adjust the plan or adjust the motion. Either way, the board and the team end up working from the same picture.
Decide What Comes First
A pressure-test usually surfaces more than one issue. The value comes from deciding which one sits furthest upstream.
A messaging gap can look like a sales problem. A buyer definition problem can look like a marketing problem. Fixing the downstream symptom first tends to produce more activity and less progress. Fixing the upstream constraint first tends to make everything after it work better.
Getting that order right is what lets a company scale with confidence.
A Quick Pressure-Test for Your Team
Before adding reps, channels, or spend, ask these five questions:
Can our team name every stakeholder in a typical buying decision and what each one needs to see?
Does our commercial story sound the same no matter who on the team tells it?
Have we clearly won our first segment, with references to prove it?
Do we know the exact stage where deals slow down, and why?
Do the assumptions in our board plan match what's actually happening in the field?
If two or more of those answers are uncertain, the plan probably needs a pressure-test before it needs more fuel.
The companies that scale well are usually the ones that tested the plan first.
At Tribe, this is the work we do with MedTech founders and CEOs every week. Our founder, Steph Pliha, has 25 years in MedTech, including bringing robotic surgery to market.
Our GTM Sprint builds the positioning, buyer strategy, and commercial roadmap a company needs before it scales. If you want a faster read, the One-Day Intensive diagnoses the commercial situation and identifies the highest-leverage priority in a single structured day.
